Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.
How this was made
The 30-second read
Why it matters
This press release is a combined financial update and pipeline progress note. Traders can reassess 2026 growth expectations using the reiterated revenue and net product sales ranges, and reprice the probability-weighted value of LUPKYNIS label expansion via the PRESERVE Phase 4 combination study.
Market read
The article provides actionable, company-specific numbers (revenue, net product sales, net income, EPS, cash position), reiterated 2026 guidance ranges, and concrete trial design details for a new Phase 4 combination study.
What to watch
Cash includes a share repurchase component, which can support EPS optics, but investors may focus on sustainability of net product sales growth and any future payer or competitive pressures not discussed here.
Background
Aurinia is the commercial-stage developer of LUPKYNIS (voclosporin) for lupus nephritis and is expanding its pipeline with aritinercept and additional LUPKYNIS studies.
Ticker impact
Aurinia reported Q2 and 6M results, reiterated 2026 revenue and net product sales guidance, and initiated the PRESERVE Phase 4 combo study for LUPKYNIS.
Moderately positive bias for the stock into the next catalyst window (trial progress and any subsequent readouts), with volatility driven by how investors underwrite LUPKYNIS growth and PRESERVE enrollment/endpoint expectations.
The article provides concrete, time-specific figures (revenue, net product sales, EPS, cash position) plus explicit 2026 guidance ranges and a specific new study initiation (PRESERVE, ~150 patients, primary endpoint CRR at 6 months). However, it does not include new efficacy results, so the clinical upside is not yet realized.
Market effects
Reinforces demand and commercial momentum for lupus nephritis therapies and may support sentiment toward specialty pharma with marketed products plus ongoing label-expansion studies.
Limited direct regional spillover; primarily US-listed biotech sentiment.
Modest global relevance as lupus nephritis is an international indication, but the disclosed catalysts are company-specific.
Counterpoint
Despite higher reported results and reiterated guidance, the clinical catalyst (PRESERVE) is early and has no efficacy data yet, so the market may already be pricing LUPKYNIS growth and discount incremental trial value.
Key entities
- companyAurinia Pharmaceuticals Inc.
NASDAQ-listed biopharmaceutical company reporting Q2 and 6M 2026 results, reiterating 2026 guidance, and initiating the PRESERVE Phase 4 study for LUPKYNIS combinations.
- productLUPKYNIS (voclosporin)
FDA-approved oral therapy for adult active lupus nephritis; net product sales were reported as $79.4M for the quarter and $153.0M for six months.
- clinical_studyPRESERVE
Phase 4 multicenter study evaluating LUPKYNIS plus belimumab, obinutuzumab, or anifrolumab; planned enrollment ~150 patients, primary endpoint CRR at 6 months.
- pipeline_assetAritinercept
Dual BAFF and APRIL inhibitor; development initiated in four potential indications.
